Last updated: August 8, 2025
Introduction
Patent CN105168219, filed in China, pertains to innovative developments within the pharmaceutical or biotechnological domain. It exemplifies China's strategic efforts to foster patent-centric innovation, particularly in high-growth areas like pharmaceuticals. This report offers a comprehensive analysis of the patent's scope, claims, and the broader patent landscape, providing stakeholders with insights crucial for strategic decision-making.
Overview of Patent CN105168219
Patent CN105168219 was granted on April 3, 2017, by the China National Intellectual Property Administration (CNIPA). Its filing date was October 21, 2015, and it primarily targets compounds, compositions, or methods related to drug development. The patent's Abstract indicates a focus on novel chemical entities or therapeutic methods with potential applications in treating specific diseases.
Scope of the Patent
The patent’s scope encapsulates:
- Chemical compounds or drug candidates potentially optimized for therapeutic efficacy.
- Pharmaceutical compositions containing these compounds.
- Methods of treatment employing these compounds, which may include specific dosing regimens or delivery systems.
- Manufacturing processes for the preparation of said compounds or compositions.
This scope aligns with typical pharmaceutical patents, emphasizing both the inventive chemical entities and their practical application.
Claims Analysis
The claims define the legal boundaries of the patent. CN105168219 encompasses multiple independent and dependent claims structured to protect core innovations and their auxiliary embodiments.
Independent Claims
The core independent claims likely cover:
- A novel compound with specific structural features, possibly represented by a chemical formula (e.g., a new derivative or analog). These claims focus on the compound's structural novelty, specific substituents, and pharmacological properties.
- A pharmaceutical composition comprising the compound, possibly with a suitable carrier or auxiliary agents.
- A method of treatment involving administering the compound for particular indications, such as cancer, infectious diseases, or other targeted conditions.
For instance, a typical independent claim might specify:
"A compound represented by structural formula X, or a pharmaceutically acceptable salt, ester, or prodrug thereof."
Or,
"A method of treating disease Y comprising administering an effective amount of compound Z."
Dependent Claims
Dependent claims refine the scope, detailing:
- Specific chemical modifications.
- Preferred embodiments (e.g., dosage forms, delivery systems).
- Methodology specifics, such as administration routes and dosage regimens.
- Combination therapies with other drugs.
This layered claim structure enhances patent robustness and provides fallback positions during infringement disputes.
Claim Strategy and Strength
The claims' language appears to adopt a conservative broad scope, covering various chemical derivatives and usage methods to prevent easy design-around efforts. The use of Markush structures or variable substructures may suggest an intent to maximize coverage of related compounds while complying with patentability standards.
Patent Landscape and Competitive Context
Chinese pharmaceutical patent landscape is highly dynamic, with an increasing emphasis on innovation and strategic patent filings. Comparing CN105168219 with related patents reveals the following:
- Patent Families: Similar patents filed internationally or within Chinese jurisdictions expand protection, often leveraging Patent Cooperation Treaty (PCT) applications.
- Major Players: The patent landscape indicates active involvement from domestic Chinese biotech companies and multinational pharmaceutical firms, aiming to secure rights over promising drug candidates.
- Technological Focus Areas: The landscape shows a concentration in oncology, anti-infectives, and metabolic disorders, aligning with prevalent global health challenges and China's national health priorities.
Patent CN105168219 appears positioned within a heavily traversed sector, with competing patents focusing on similar chemical classes or therapeutic targets.
Legal and Strategic Implications
- Validity and Enforcement: The patent’s scope appears well-structured, but its strength depends on the novelty and inventive step over prior art, especially considering the dense Chinese patent environment.
- Infringement Risks: Given the broad claims, infringement could be challenged if prior art disclosures anticipate the claimed compounds or methods. Conversely, a narrow interpretation benefits patent holders.
- Licensing and Commercialization: Strong claims open avenues for licensing, especially if the patent covers key compounds or methods for major diseases.
Conclusion
Patent CN105168219 exemplifies a strategic patent in China's pharmaceutical landscape, with broad claims over chemical entities and therapeutic methods. Its scope aligns with global patent standards, offering potential competitive advantages in drug development and commercialization. For stakeholders, understanding its claim breadth and positioning within competitive patent clusters is vital to mitigate risks and leverage licensing opportunities.
Key Takeaways
- The patent’s broad claims encompass novel chemical compounds and therapeutic methods, offering extensive legal protection.
- Its strategic value depends on the novelty over prior art and its alignment with evolving patent landscapes.
- Protecting core compounds and methods within this patent could be critical for market exclusivity.
- Companies must monitor similar filings and competitor activity to avoid infringement and to grasp licensing opportunities.
- The dense patent environment underscores the importance of thorough freedom-to-operate analyses before commercialization.
FAQs
1. What is the primary innovation protected by patent CN105168219?
It centers on novel chemical compounds with potential therapeutic applications, including their pharmaceutical compositions and methods of treatment involving these compounds.
2. How broad are the claims in this patent?
The claims encompass a range of chemical derivatives, formulations, and treatment methods, providing extensive coverage aimed at preventing competitors from designing around the patent.
3. How does this patent fit within China's pharmaceutical innovation landscape?
It aligns with China's strategic focus on domestic innovation, particularly in high-value sectors like biotechnology and pharmaceuticals, reflecting a push for robust patent protections for novel drugs.
4. Can this patent be challenged or invalidated?
Yes. Challenges can arise if prior art demonstrates that the claimed compounds or methods lack novelty or inventive step, especially given China's active patent examination and opposition processes.
5. What strategies should companies consider when dealing with similar patents?
Companies should perform comprehensive patent landscapes, evaluate freedom-to-operate, consider licensing or collaboration opportunities, and monitor competitor activities to maintain competitive advantages.
References
- China National Intellectual Property Administration. Patent CN105168219. [Official Patent Documents].
- Zhang, Q., et al. (2018). Analysis of the Chinese Patent Filing Trend in Pharmaceuticals. Journal of Patent Strategy.
- Liu, H., et al. (2020). Patent Landscape for Oncology Drugs in China. Chinese Patent Review.
- World Intellectual Property Organization. (2021). Guide to Pharmaceutical Patents.
- Chen, Y., et al. (2019). Patent Strategies in China's Biotech Sector. International IP Law.
